Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 3—March 2012
Letter

Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands

Esther H. Fietjé, Daphne PhilbertComments to Author , Erica C.G. van Geffen, Nina A. Winters, and Marcel L. Bouvy
Author affiliations: Author affiliation: Utrecht University, Utrecht, the Netherlands

Main Article

Table

Reported risk factors of patients with and without influenza symptoms who were dispensed a prescription for oseltamivir, the Netherlands, 2009–10

Risk factor No. (%) patients*
Total, n = 300 Influenza symptoms, n = 223 No influenza symptoms, n = 77
Chronic condition 211 (70.3) 154 (69.1) 57 (74.0)
Chronic respiratory disease 127 (42.3) 98 (43.9) 29 (37.7)
Lower immune resistance caused by illness or medical treatment 76 (25.3) 50 (22.4) 26 (33.8)
Cardiovascular disease 52 (17.3) 34 (15.2) 18 (23.4)
Diabetes 44 (14.7) 28 (12.6) 16 (20.8)
Renal disease 10 (3.3) 5 (2.2) 5 (6.5)
Other 125 (41.7) 86 (38.6) 39 (50.6)
Age >60 y 66 (22.0) 35 (15.7) 31 (40.3)
Age <2 y 36 (12.0) 35 (15.7) 1 (1.3)
Regular patient contact by health care worker 22 (7.3) 15 (6.7) 7 (9.1)
Pregnancy 5 (1.7) 2 (0.9) 3 (3.9)
No. risk factors
0 44 (14.7) 34 (15.2) 10 (13.0)
1 137 (45.7) 111 (49.8) 26 (33.8)
2 72 (24.0) 53 (23.8) 19 (24.7)
>3 47 (15.7) 25 (11.2) 22 (28.6)

*Percentages may total >100% because of rounding.

Main Article

Page created: February 16, 2012
Page updated: February 16, 2012
Page reviewed: February 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external